Ipca Laboratories surges on inking agreement for creation of Strategic Biosimilars

03 Jun 2014 Evaluate

lpca Laboratories is currently trading at Rs. 797.55, up by 9.30 points or 1.18% from its previous closing of Rs. 788.25 on the BSE.

The scrip opened at Rs. 800.00 and has touched a high and low of Rs. 808.80 and Rs. 791.20 respectively. So far 12,000 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 906.90 on 28-Feb-2014 and a 52 week low of Rs. 590.00 on 03-Jun-2013.

Last one week high and low of the scrip stood at Rs. 812.40 and Rs. 769.10 respectively. The current market cap of the company is Rs. 10,054.00 crore.

The promoters holding in the company stood at 45.89% while Institutions and Non-Institutions held 36.74% and 17.36% respectively.

Ipca Laboratories (Ipca) and US-based Oncobiologics, Inc. have entered into an agreement for creation of a two-part alliance for the development, manufacture and commercialization of biosimilar monoclonal antibody products.

Under the first part of the agreement, Ipca will in-license and commercialize biosimilar products for the India and associated markets. These products will be developed by Oncobiologics to USFDA and EU regulatory standards for global commercialization. Initial manufacturing will occur in the USA by Oncobiologics and later by Ipca in India. The biologics covered by the agreement are among the most popular therapies in the world for immunology and oncology disease indications. The partnership is planning to launch the first product in 2017.

Under the second part of the agreement, Oncobiologics will replicate its Biologics R&D and manufacturing facility in India to create a world-class capability for Ipca for further biosimilar commercialization.

The Mumbai R&D facility will be designed for development and commercialization of complex monoclonal antibodies. The Manufacturing facility will be located in Vadodara and will utilize the latest single-use manufacturing platform. The R&D facility will be operational from 2015 and the manufacturing facility will be operational by 2016.

Ipca Laboratories Share Price

1459.30 2.15 (0.15%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×